Keeping Track: Approval Of First Intranasal Naloxone Copycat Highlights Otherwise Generic Week
Viela Bio's inebilizumab for NMOSD and Genfit's elafibranor for PBC win breakthrough designations; Novartis uses priority review voucher for wet AMD treatment brolucizumab.
